WHAT IS CLAIMED IS:

1. A cyclic tetrapeptide derivative represented by the following general formula (I), (I'), (I'') or (I''') or a pharmaceutically acceptable salt thereof:



(I)



(I')



(I'')



(I''')

wherein each of R_{11}, R_{12}, R_{21} and R_{22} independently denotes hydrogen, a linear C_1-C_6-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached, or a branched C_3-C_6-alkyl group to which a non-aromatic cycloalkyl group or an optionally substituted aromatic ring may be attached; and

each of R_1, R_2 and R_3 independently denotes a linear C_1-C_5-alkylene group which may have a C_1-C_6 side chain, in which the side chain may form a condensed ring structure on the alkylene chain;

provided that at least one of R_{11}, R_{12}, R_{21} and R_{22} in general formula (I''') is a cyclohexyl methyl group.

2. The cyclic tetrapeptide derivative according to claim 1, which is represented by said general formula (I), or a pharmaceutically acceptable salt thereof.

3. The cyclic tetrapeptide derivative according to claim 1, which is represented by said general formula (I'), or a pharmaceutically acceptable salt thereof.

4. The cyclic tetrapeptide derivative according to claim 1, which is represented by said general formula (I''), or a pharmaceutically acceptable salt thereof.

5. The cyclic tetrapeptide derivative according to claim 1, which is represented by said general formula (I'''), or a pharmaceutically acceptable salt thereof.

6. A histone deacetylase inhibitor comprising the cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 as an active ingredient.

7. An MHC class-I molecule expression-promoting agent comprising the cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 as an active ingredient.

8. A pharmaceutical composition comprising the cyclic tetrapeptide derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 as an active ingredient.

9. The pharmaceutical composition according to claim 8, which is used as an anti-cancer agent.